JP6764408B2 - Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与 - Google Patents

Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与 Download PDF

Info

Publication number
JP6764408B2
JP6764408B2 JP2017533485A JP2017533485A JP6764408B2 JP 6764408 B2 JP6764408 B2 JP 6764408B2 JP 2017533485 A JP2017533485 A JP 2017533485A JP 2017533485 A JP2017533485 A JP 2017533485A JP 6764408 B2 JP6764408 B2 JP 6764408B2
Authority
JP
Japan
Prior art keywords
influenza
seq
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017533485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501258A5 (https=
JP2018501258A (ja
Inventor
テッド ミルバーン ロス
テッド ミルバーン ロス
ティム アレファンティス
ティム アレファンティス
ドナルド マーティン ジュニア カーター
ドナルド マーティン ジュニア カーター
クリストファー オースティン ダービー
クリストファー オースティン ダービー
ハロルド クリーンソウス
ハロルド クリーンソウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of JP2018501258A publication Critical patent/JP2018501258A/ja
Publication of JP2018501258A5 publication Critical patent/JP2018501258A5/ja
Application granted granted Critical
Publication of JP6764408B2 publication Critical patent/JP6764408B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017533485A 2014-12-19 2015-12-18 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与 Expired - Fee Related JP6764408B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094772P 2014-12-19 2014-12-19
US62/094,772 2014-12-19
PCT/US2015/066882 WO2016100922A1 (en) 2014-12-19 2015-12-18 Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020131336A Division JP2020186252A (ja) 2014-12-19 2020-08-03 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与

Publications (3)

Publication Number Publication Date
JP2018501258A JP2018501258A (ja) 2018-01-18
JP2018501258A5 JP2018501258A5 (https=) 2019-01-31
JP6764408B2 true JP6764408B2 (ja) 2020-09-30

Family

ID=56127736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017533485A Expired - Fee Related JP6764408B2 (ja) 2014-12-19 2015-12-18 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与
JP2020131336A Pending JP2020186252A (ja) 2014-12-19 2020-08-03 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020131336A Pending JP2020186252A (ja) 2014-12-19 2020-08-03 Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与

Country Status (7)

Country Link
US (2) US10220086B2 (https=)
EP (1) EP3233116A4 (https=)
JP (2) JP6764408B2 (https=)
CN (1) CN107530417A (https=)
AU (1) AU2015364253B2 (https=)
CA (1) CA2970158A1 (https=)
WO (1) WO2016100922A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970158A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019108319A1 (en) * 2017-12-01 2019-06-06 Kemin Industries, Inc. Compositions containing euglena gracilis for viral protection and related methods
US12521430B2 (en) 2018-03-28 2026-01-13 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
JP2024522193A (ja) * 2021-06-10 2024-06-11 ユニバーシティ オブ ジョージア リサーチ ファウンデイション， インコーポレイテッド 免疫原としての広範囲反応性ウイルス抗原、その組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
USH2283H1 (en) * 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2868330A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
SG11201503989PA (en) * 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
KR20150138184A (ko) * 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
CA2970158A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US20200237898A1 (en) * 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza

Also Published As

Publication number Publication date
US20170368164A1 (en) 2017-12-28
WO2016100922A1 (en) 2016-06-23
JP2020186252A (ja) 2020-11-19
CA2970158A1 (en) 2016-06-23
EP3233116A1 (en) 2017-10-25
AU2015364253B2 (en) 2020-01-23
US20190175721A1 (en) 2019-06-13
US10925957B2 (en) 2021-02-23
US10220086B2 (en) 2019-03-05
JP2018501258A (ja) 2018-01-18
CN107530417A (zh) 2018-01-02
AU2015364253A1 (en) 2017-06-29
EP3233116A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
US10925957B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
Brazzoli et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin
US10548965B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
Magini et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge
Altenburg et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
Moser et al. Influenza virosomes as a vaccine adjuvant and carrier system
AU2021200727A1 (en) Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10485864B2 (en) Characterization of influenza vaccines
Lofano et al. B cells and functional antibody responses to combat influenza
Yager et al. Prospects for developing an effective particle-mediated DNA vaccine against influenza
Di et al. The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice
Zhang et al. Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses
JP7479424B2 (ja) 改変インフルエンザヘマグルチニンポリペプチドの修飾
JP2024540290A (ja) ヘマグルチニン及びノイラミニダーゼを含むハイブリッド多価インフルエンザワクチン及びそれを使用する方法
Geeraedts et al. Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine
KR20190137385A (ko) 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신
EP3303368A2 (en) Engineered influenza antigenic polypeptides and immunogenic compositions thereof
Hoxie et al. A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses
Ebensen et al. Preclinical Animal Models for Developing Vaccines Against Influenza Infection for the Young and the Elderly

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200803

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200911

R150 Certificate of patent or registration of utility model

Ref document number: 6764408

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees